Senseonics (NYSE:SENS) posted fourth-quarter results that proved mixed compared to Wall Street forecasts alongside a major pipeline announcement.
STOCKHOLM, March 2, 2026 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure
DENVER, March 2, 2026 /PRNewswire/ — Ultrasound AI, a pioneer in artificial intelligence applications for medical imaging, today announced it has received FDA De Novo clearance for its flagship Delivery Date AI technology, a cloud-based SaMD that determines a Predicted Delivery Date (PDD) solely from standard ultrasound images and seamless integration into current OB/MFM prenatal visit workflows; PDD is provided in real-time for actionable decision-making by the clinical team.
Lasers cut precisely and without contact—ideal for surgery. The problem is that in hard tissues such as bone, they are too slow and do not cut deep enough. Researchers at the University of Basel have now demonstrated a way to cut much deeper and faster with a surgical laser than with previous laser systems.
Synergy Spine Solutions®, a medical device company focused on improving the quality of life for patients undergoing spine surgery, today announced it has received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Synergy Disc® for 1-level indications at C3-C7.
Gene therapy has been successfully used to treat a number of diseases, including immune deficiencies, hereditary blindness, hemophilia and, recently, Huntington’s disease, a fatal neurological disorder.
An AI can accurately diagnose a rare endocrinological condition just by analyzing pictures of the back of the hand and the clenched fist. The privacy-conscious achievement by Kobe University holds promise for establishing more efficient referral systems and reducing health care disparities across communities.
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.
TechLive is a multimodality, vendor-agnostic remote scanning and radiology management solution extending expert oversight across multiple modalities
Abbott (NYSE: ABT)+ today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.